Castle Biosciences/$CSTL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Castle Biosciences
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
- Ticker
- $CSTL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,002
- Headquarters
- Friendswood, United States
- Website
- castlebiosciences.com
CSTL Metrics
BasicAdvanced
$1B
-
-$0.65
0.97
-
Price and volume
Market cap
$1B
Beta
0.97
52-week high
$44.28
52-week low
$17.72
Average daily volume
348K
Financial strength
Current ratio
6.036
Quick ratio
5.602
Long term debt to equity
0.069
Total debt to equity
0.078
Interest coverage (TTM)
-32.02%
Profitability
EBITDA (TTM)
-16.516
Gross margin (TTM)
77.26%
Net profit margin (TTM)
-5.43%
Operating margin (TTM)
-3.36%
Effective tax rate (TTM)
-1.10%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
-1.36%
Return on equity (TTM)
-4.20%
Valuation
Price to revenue (TTM)
2.721
Price to book
2.13
Price to tangible book (TTM)
2.67
Price to free cash flow (TTM)
-1,988.347
Free cash flow yield (TTM)
-0.05%
Free cash flow per share (TTM)
-0.016
Growth
Revenue change (TTM)
3.18%
Earnings per share change (TTM)
96.09%
3-year revenue growth (CAGR)
28.72%
3-year earnings per share growth (CAGR)
-42.00%
What the Analysts think about CSTL
Analyst ratings (Buy, Hold, Sell) for Castle Biosciences stock.
Analyst projections of the future price of Castle Biosciences stock.
Bulls say / Bears say
Second-quarter revenue rose 20% year on year and reports for DecisionDx-Melanoma and TissueCypher grew 32%. Castle raised its 2026 revenue outlook to $365–375 million and expects full-year adjusted EBITDA to be positive. (PR Newswire)
A September study found TissueCypher changed clinicians’ management recommendations for 90% of 30 patients with non-dysplastic Barrett’s oesophagus. While the study was small, it offers evidence that the test can influence care decisions and support further adoption. (Castle Biosciences)
New prospective, multi-centre data from 2,799 melanoma patients found five-year recurrence-free survival of 99.6% among low-risk patients who did not undergo sentinel lymph node biopsy. This supports the potential value of DecisionDx-Melanoma in helping clinicians identify patients who may safely avoid the procedure. (Castle Biosciences)
Medicare coverage for DecisionDx-SCC remains unsettled following a coverage change, and Castle has no firm timetable for a decision on its request for reconsideration. Even a positive draft decision might not restore coverage until roughly a year later, leaving a potential revenue recovery some way off. (Castle Biosciences, MarketBeat)
Revenue growth has not yet translated into consistent GAAP profit: Castle reported a $2.1 million second-quarter net loss, versus net income a year earlier, and used $6.9 million of cash in operations in the first half. This leaves execution on cost control and sustained profitability as important risks. (Castle Biosciences)
AdvanceAD-Tx is a potential new product, but Castle does not expect significant revenue from it in 2026 and still needs to work through reimbursement requirements. That delays the opportunity to add a new growth stream and leaves its commercial contribution uncertain. (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
CSTL Financial Performance
Revenues and expenses
CSTL Earnings Performance
Company profitability
Upcoming events
No upcoming events
CSTL News
AllArticlesVideos
Funds containing CSTL
AllUSDEURGBP
Fund name | Fund size | $CSTL weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.11% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.11% |
iShares Healthcare Innovation£DRDR | £1B | 0.11% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.07% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.